Implications of EGFR inhibition in ovarian cancer cell proliferation

Gynecologic Oncology

Volumn 109, Issue 3, 2008, Pages 411-417

  Bull Phelps, Shawna L ^a   Schorge, John O ^a   Peyton, Michael J ^b   Shigematsu, Hisayuki ^b   Xiang, Li Lin ^b   Miller, David S ^a   Lea, Jayanthi S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

EGFR; Gefitinib; HER; Monoclonal antibody; Ovarian cancer; Tyrosine kinase

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GEFITINIB;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; EXON; FEMALE; GENE DELETION; GENE INSERTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; LUNG CANCER; MISSENSE MUTATION; MUTATIONAL ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 44549088669     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.02.030     Document Type: Article

References (40)

1. Psyrri A., Kassar M., Yu Z., Bamias A., Weinberger P.M., Markakis S., Kowalski D., et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 11 24 Pt 1 (2005 Dec 15) 8637-8643
2. Seiden M.V., Burris H.A., Matulonis U., Hall J.B., Armstrong D.K., Speyer J., Weber J.D., et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 104 3 (Mar 2007) 727-731
3. Shepard H.M., Lewis G.D., Sarup J.C., Fendly B.M., Maneval D., Mordenti J., Figari I., et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11 3 (1991 May) 117-127
4. Green M.R. Targeting targeted therapy. N Engl J Med 350 21 (2004 May 20) 2191-2193
5. Gazdar A.F., Shigematsu H., Herz J., and Minna J.D. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. Trends Mol Med 10 10 (Oct 2004) 481-486
6. Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 16 4 (Apr 2005) 538-548
7. Vaidya A.P., Parnes A.D., and Seiden M.V. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies. Curr Treat Opt Oncol 6 2 (Mar 2005) 103-114
8. Kiley S.C., and Chevalier R.L. Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF. Am J Physiol Renal Physiol 293 3 (Sep 2007) F895-F903
9. Minna J.D., Peyton M.J., and Gazdar A.F. Gefitinib versus cetuximab in lung cancer: round one. J Natl Cancer Inst 97 16 (Aug 17 2005) 1168-1169
10. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., and Gibson K.H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research 62 20 (2002 Oct 15) 5749-5754
11. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B.J., et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16 10 (1996 Oct) 5276-5287
12. Ono M., Hirata A., Kometani T., Miyagawa M., Ueda S., Kinoshita H., Fujii T., et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3 4 (2004 Apr) 465-472
13. Cooper J.A., and Howell B. The when and how of Src regulation. Cell 73 6 (Jun 18 1993) 1051-1054
14. Emlet D.R., Moscatello D.K., Ludlow L.B., and Wong A.J. Subsets of epidermal growth factor receptors during activation and endocytosis. J Biol Chem 272 7 (1997 Feb 14) 4079-4086
15. Ettenberg S.A., Keane M.M., Nau M.M., Frankel M., Wang L.M., Pierce J.H., and Lipkowitz S. cbl-b inhibits epidermal growth factor receptor signaling. Oncogene 18 10 (Mar 11 1999) 1855-1866
16. Rojas M., Yao S., and Lin Y.Z. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 271 44 (Nov 1 1996) 27456-27461
17. Feng S.M., Sartor C.I., Hunter D., Zhou H., Yang X., Caskey L.S., Dy R., et al. The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. Mol Endocrinol 21 8 (Aug 2007) 1861-1876
18. Lacroix L., Pautier P., Duvillard P., Motté N., Saulnier P., Bidart J.M., and Soria J.C. Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. Int J Cancer 118 4 (Feb 15 2006) 1068-1069
19. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 9 (May 4 2005) 643-655
20. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., and Moasser M.M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445 7126 (Jan 25 2007) 437-441
21. Niikura H., Sasano H., Sato S., and Yajima A. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol 16 1 (Jan 1997) 60-68
22. Sewell J.M., Macleod K.G., Ritchie A., Smyth J.F., and Langdon S.P. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). Br J Cancer 86 3 (Feb 1 2002) 456-462
23. Cowden Dahl K.D., Zeineldin R., and Hudson L.G. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res 5 5 (May 2007) 413-421
24. Schilder R.J., Sill M.W., Chen X., Darcy K.M., Decesare S.L., Lewandowski G., Lee R.B., et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin Cancer Res 11 15 (Aug 1 2005) 5539-5548
25. Posadas E.M., Liel M.S., Kwitkowski V., Minasian L., Godwin A.K., Hussain M.M., Espina V., et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109 7 (Apr 1 2007) 1323-1330
26. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., Peyton M., et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65 1 (Jan 1 2005) 226-235
27. Lea J., Ashfaq R., Muneer S., Burbee D., Miller D., Minna J., and Muller C. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development. J Soc Gynecol Investig 11 5 (Jul 2004) 329-337
28. Grunwald V., and Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95 12 (Jun 18 2003) 851-867
29. Barker A.J., Gibson K.H., Grundy W., Godfrey A.A., Barlow J.J., Healy M.P., Woodburn J.R., et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11 14 (Jul 23 2001) 1911-1914
30. Stewart C.J., Owens O.J., Richmond J.A., and McNicol A.M. Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors. Int J Gynecol Pathol 11 4 (Oct 1992) 266-272
31. Hirata A., Hosoi F., Miyagawa M., Ueda S., Naito S., Fujii T., Kuwano M., et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 65 10 (May 15 2005) 4253-4260
32. Moulder S.L., Yakes F.M., Muthuswamy S.K., Bianco R., Simpson J.F., and Arteaga C.L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61 24 (Dec 15 2001) 8887-8895
33. Anido J., Matar P., Albanell J., Guzman M., Rojo F., Arribas J., Averbuch S., et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9 4 (Apr 2003) 1274-1283
34. Emlet D.R., Moscatello D.K., Ludlow L.B., and Wong A.J. Subsets of epidermal growth factor receptors during activation and endocytosis. J Biol Chem 272 7 (Feb 14 1997) 4079-4086
35. Sewell J.M., Smyth J.F., and Langdon S.P. Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration. Exp Cell Res 304 1 (Mar 10 2005) 305-316
36. Das A.K., Sato M., Story M.D., Peyton M., Graves R., Redpath S., Girard L., et al. Non-small cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 66 19 (2006) 9601-9608
37. Gordon A.N., Finkler N., Edwards R.P., Garcia A.A., Crozier M., Irwin D.H., and Barrett E. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15 5 (Sep-Oct 2005) 785-792
38. Alvarez Secord A., Blessing J.A., Armstrong D., Barnes M.N., Lewandowski G., and Mannel R.S. Phase II study of cetuximab in combination with carboplatin in patients with relapsed platinum-sensitive ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol 104 3 (2007) S32 Absract#74
39. Wu Y.L., Zhong W.Z., Li L.Y., Zhang X.T., Zhang L., Zhou C.C., Liu W., et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2 5 (May 2007) 430-439
40. Van Schaeybroeck S., Kyula J., Kelly D.M., Karaiskou-McCaul A., Stokesberry S.A., Van Cutsem E., Longley D.B., et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 5 5 (May 2006) 1154-1165